Cellect Biotechnology Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Cellect Biotechnology Ltd., a foreign private issuer, on November 9, 2020. The report covers the reconvened annual general meeting of shareholders held on November 8, 2020.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document serves as a procedural report regarding shareholder meeting outcomes rather than a financial statement.
Material Changes
At the reconvened annual general meeting on November 8, 2020, the Company's ordinary shareholders and ADS holders passed all agenda items as proposed. These items were previously described in Exhibit 99.1 of a Form 6-K furnished on October 20, 2020.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The document is limited to confirming the successful passage of shareholder agenda items.
Key Facts for Investor Verification
- Verify the specific agenda items passed by shareholders by reviewing Exhibit 99.1 of the October 20, 2020 Form 6-K.
- Confirm that the reconvened meeting on November 8, 2020, resulted in the approval of all proposed items without dissent.
- Note that this filing does not contain updated financial performance data for the period.